Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc. (symbol: RBOT) is at the forefront of innovation in the field of surgical robotics. The company is dedicated to enhancing the capabilities of surgeons and improving patient outcomes through advanced technological solutions. Vicarious Surgical has developed a unique surgical robot that combines human-like dexterity with the world's first virtual-reality surgical camera, enabling surgeons to perform minimally invasive procedures with the same ease as traditional open surgery.
The company’s flagship product, the Vicarious Surgical Robotic System, is specifically designed for abdominal surgeries. It offers 3D visualization and precise control, all through a single port, which significantly reduces the invasiveness of surgical procedures. This groundbreaking technology aims to expand global access to high-quality surgical care.
Vicarious Surgical's approach redefines what is possible in surgical robotics by integrating cutting-edge virtual reality and robotics technology. The company has achieved significant milestones in recent years, including key partnerships and notable advancements in their robotic systems.
Financially, Vicarious Surgical continues to show promise with robust investments and strategic collaborations that drive its growth and innovation. The company remains committed to pushing the boundaries of medical technology, with ongoing projects focused on further enhancing their systems and expanding their applications.
For investors and stakeholders, Vicarious Surgical represents a compelling opportunity in the rapidly evolving field of medical technology. The company’s mission to improve surgical outcomes and patient care through revolutionary robotics sets it apart as a leader in the industry.
Stay updated with the latest news and developments from Vicarious Surgical to understand its impact and progress in the surgical robotics landscape.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will report its financial results for the fourth quarter and full year ended December 31, 2022, after market close on February 13, 2023. A conference call will follow at 4:30 p.m. ET for management to discuss the results. Investors can join by calling +1 (646) 904 5544 domestically or +1 (929) 526 1599 internationally. The company develops advanced surgical robotics aimed at improving the efficiency of procedures and reducing costs, using proprietary technology to perform minimally invasive surgeries.
Vicarious Surgical Inc. (NYSE:RBOT) has appointed Dr. Victoria Carr-Brendel to its Board of Directors as of January 23, 2023. Dr. Carr-Brendel brings over 24 years of experience in medical device development and leadership roles, including her current position at Sonova Group. Her expertise is expected to enhance the company's efforts in bringing innovative surgical solutions to market. The announcement also includes the resignation of Phil Liang, a technology-focused venture capitalist. The company aims to improve surgical procedures' efficiency, outcomes, and costs through its unique robotic systems.
Vicarious Surgical Inc. (NYSE:RBOT) demonstrated its Beta 2 surgical robotic platform on December 6, 2022, highlighting advancements in technology and successful cadaveric testing. CEO Adam Sachs emphasized the importance of this milestone, while surgeon Dr. Igor Belyansky showcased the system’s innovative capabilities in a recent procedure. Collaborating with University Hospitals, the company aims to improve minimally invasive surgery outcomes. Vicarious Surgical leads in developing robotic technology to enhance surgical efficiency and patient care.
Vicarious Surgical (NYSE:RBOT) announced the successful use of its Beta 2 prototype for cadaveric ventral hernia repairs by renowned surgeon Igor Belyansky. This milestone, showcasing advanced robotic surgical capabilities, is set to be highlighted on December 6, 2022, during Vicarious Surgical's Beta 2 Demonstration Day. The prototype aims to improve surgical efficiency and patient outcomes through minimally invasive techniques using a single-port approach. The collaboration with Belyansky underscores the company's commitment to innovation in robotic surgery.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will participate in two upcoming investor conferences. The company, specializing in next-generation robotics to enhance surgical procedures, will host a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 3:05 p.m. ET, followed by another chat at the 34th Annual Piper Sandler Healthcare Conference on November 30 at 1:00 p.m. ET. Interested investors can access the presentations live or archived via the company's website.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announces that its robotic system has been included in TIME's Best Inventions of 2022, recognized for its innovative design. The system utilizes one camera and two multi-jointed arms for minimally invasive surgeries, demonstrating a full replication of the surgeon's movements. The company completed its Beta 2 system design earlier this year and plans to showcase it on December 6, 2022. The technology has received FDA Breakthrough Device Designation, aiming to enhance surgical efficiency while reducing healthcare costs.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced its financial results for Q3 2022, reporting a significant increase in operating expenses to $22.2 million, up 159% from $8.6 million the previous year. R&D expenses rose to $12.1 million, while adjusted net loss was $21.7 million, or $0.18 per share, compared to a loss of $8.6 million, or $0.09 per share, in Q3 2021. The GAAP net loss was $24.7 million, down from $45.1 million year-over-year. The company ended the quarter with $126.8 million in cash and equivalents, maintaining a cash burn rate of $14.5 million.
Vicarious Surgical Inc. has signed a collaborative Memorandum of Understanding with Pittsburgh CREATES, enhancing its development of robotic surgical solutions. The partnership aims to leverage academic and clinical resources from the University of Pittsburgh and UPMC to improve surgical procedures' efficiency, outcomes, and cost-effectiveness.
This collaboration extends Vicarious Surgical's existing partnerships, providing access to a network of clinical and operational robotic experts.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) plans to release its third quarter 2022 financial results on November 7, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern Time. This company focuses on enhancing surgical procedures through innovative robotics aimed at improving efficiency and reducing healthcare costs. Founded in 2014, Vicarious Surgical is supported by notable investors including Bill Gates and Khosla Ventures. Investors can access the call by dialing +1 (646) 904 5544 (domestic) or +1 (929) 526 1599 (international).
Vicarious Surgical Inc. announced the resignation of board members Dror Berman and Samir Kaul effective October 18, 2022. The company appointed Beverly Huss to the board on the same date, where she will serve on the Audit Committee. Huss brings extensive experience in medical devices and has previously held CEO positions at companies like Pagonia Medical and Qool Therapeutics. The company aims to enhance surgical procedures through innovative robotic technology.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
What does Vicarious Surgical Inc. specialize in?
What is the Vicarious Surgical Robotic System?
How does Vicarious Surgical's technology benefit surgeons?
What makes Vicarious Surgical's approach unique?
Where can I find the latest news about Vicarious Surgical Inc.?
What are the recent achievements of Vicarious Surgical Inc.?
How does the Vicarious Surgical Robotic System improve patient outcomes?
Is Vicarious Surgical Inc. involved in any partnerships?
What is the focus area of Vicarious Surgical's robotic system?
How does Vicarious Surgical's technology expand global access to surgical care?
